7Fconnect Spółka z Ograniczoną Odpowiedzialnością (KRS 0000891406, NIP 7133112210) is a Polish company, headquartered in Lublin, Lubelskie voivodeship. 7Fconnect operates in: Scientific research and development (PKD 72.10.Z). Industry: Research and development. The company has been listed in the National Court Register since March 26, 2021. 7Fconnect's most recently reported net revenue was 22.5 K PLN for 2024.
Negative equity
Negative equity in 4 of 4 available reporting years.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - 7Fconnect
Identity
- Name
- 7Fconnect Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- Limited Liability Company (LLC)
- Founded
- March 26, 2021
- Registry status as of
- July 16, 2026
- Latest entry
- July 16, 2026
- Founding act
- AKTEM NOTARIALNYM Z DNIA 17.03.2021 R. REP. A NR 1141/2021 SPORZĄDZONYM PRZEZ ZBIGNIEWA KRAWCZAKA NOTARIUSZA W WARSZAWIE…
Articles of association history (4)
- March 17, 2021: AKTEM NOTARIALNYM Z DNIA 17.03.2021 R. REP. A NR 1141/2021 SPORZĄDZONYM PRZEZ ZBIGNIEWA KRAWCZAKA NOTARIUSZA W WARSZAWIE ZAWARTO UMOWĘ SPÓŁKI.
- April 26, 2022: 26.04.2022 R., REP. A NR 2982/2022, NOTARIUSZ EDYTA CZARTORYSKA-GANCZEWSKA, KANCELARIA NOTARIALNA W WARSZAWIE, UCHYLENIE CAŁEGO DOTYCHCZASOWEGO TEKSTU UMOWY SPÓŁKI I PRZYJĘCIE NOWEGO
- January 25, 2024: 25.01.2024 R. REP. A NR 465/2024, NOTARIUSZ EWELINA STYGAR-JAROSIŃSKA, KANCELARIA NOTARIALNA W WARSZAWIE, ZMIANA § 1 UST. 4 UMOWY SPÓŁKI POPRZEZ NADANIE NOWEGO BRZMIENIA.
- December 19, 2025: 19.12.2025 R., AKT NOTARIALNY REP. A NR 6431/2025, NOTARIUSZ EWELINA STYGAR-JAROSIŃSKA, KANCELARIA NOTARIALNA W WARSZAWIE, ZMIANA § 1 UST. 2 I UST. 3 ORAZ § 2 UST. 1 UMOWY SPÓŁKI POPRZEZ NADANIE NOWEGO BRZMIENIA.
Activities
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. KOWALSKA, 5, 203, 20-115, LUBLIN, POLSKA
- Voivodeship
- LUBELSKIE
- District
- LUBLIN
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-32689-16702-FCWDW-16
Risk and payment profile - 7Fconnect
Credibility rating
1 / 100
Very poor credibility
Insolvency risk
Very high
Significant formal threat
Closure risk
46
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
Spółka wykazuje sygnały niestabilności organizacyjnej: częste zmiany w zarządzie. Może to wskazywać na podwyższone ryzyko współpracy.
Shareholder changes
2
2/5 yrs
Board changes
4
4/5 yrs
PKD changes
1
1/5 yrs
Name changes
1
1/5 yrs
Data from 5 years of registry activity.
Credibility history
Payment reliability score from 2021–2024
Current: E (1/100)
Trend: deteriorating (-9.5 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2021–2024
Current: 267.75 PLN
Safe: 26.78 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - 7Fconnect
Founded
March 26, 2021
5 years in operation
Legal form
Limited Liability Company (LLC)
Registry: RejP
Headquarters
LUBLIN
LUBELSKIE
Primary PKD
72.10.Z
Scientific research and development
Share capital
5.0 K PLN
100 shares total
Shareholders
2
shareholders
Board
1 person
Filed years
4 years
2021–2024 · profitable: 0/4
Registry entries
29
latest: July 16, 2026
Risk signals
Revenue
22.5 K PLN
2024
Net profit
-1.2 M PLN
2024
Assets
3.1 M PLN
2024
Equity
-6.2 M PLN
2024
EBITDA
-527.0 K PLN
2024
Board and connected people - 7Fconnect
People holding roles at 7Fconnect according to the Polish National Court Register. Follow a name for that person's full profile and their other companies.
- Krzysztof Aleksander WitońPresident of the board, Majority shareholder, Commercial proxy
- Monika KozakPresident of the board
- Tomasz Andrzej NasiłowskiPresident of the board
- Wojciech MaślanyPresident of the board
- Andrzej RóżańskiBoard member
- Paweł CichoszCommercial proxy
Directories and rankings for this location
Public procurement
Trademarks
Reviews
Rate business credibility - 7Fconnect.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.